Triflusal antiplatelets drug

Description Results NMA

triflusal 600 mg daily (n=1135)

vs.

aspirine 300 mg daily (n=1140)

double blind

Parallel groups

Sample size: 1135/1140

Primary endpoint: cardiovascular events

FU duration: 35 days

Non-fatal MI 0.34 [0.14; 0.84]

Vasc events 0.45 [0.20; 1.02]

revascularization 0.83 [0.51; 1.35]

Major bleeds NaN [NaN; NaN]

Vasc deaths ∞ [NaN; ∞]

Non vasc deaths NaN [NaN; NaN]

cardiovascular events 0.45 [0.20; 1.02]

triflusal 300 mg three times daily (n=143)

vs.

placebo (n=138)

double blind

Parallel groups

Sample size: 143/138

Primary endpoint:

FU duration: 6m

non fatal TE events,bleedings and vascular death* 1.45 [0.77; 2.72]

non fatal stroke 3.29 [0.92; 11.81]

thromboembolic event likes(TE event or ischemic stroke or systemic embolism) 2.12 [0.88; 5.09]

Triflusal 600 mg/d (n=242)

vs.

coumadin standard dose(target INR 2-3) (n=237)

Open

Parallel groups

Sample size: 242/237

Primary endpoint: vascular death,TIA,nonfatal stroke or systemic embolism

FU duration: 2.76 years

Withdrawals from study treatments are not reported separetely:9% were withdrawn for adverse events without significant difference among groups,9.3% were withdrawn secondary to gp or patient's decision.